Phase I, First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of MS201408-0005A as Single Agent and Sequentially in Combinations With MS201408-0005C or MS201408-0005B in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors

Trial Profile

Phase I, First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of MS201408-0005A as Single Agent and Sequentially in Combinations With MS201408-0005C or MS201408-0005B in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs MS-201408-0005-A-EMD-Serono (Primary) ; MS-201408-0005B-EMD-Serono (Primary) ; MS-201408-0005C-EMD-Serono (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors EMD Serono Research & Development Institute
  • Most Recent Events

    • 18 Jul 2018 Planned End Date changed from 24 Jan 2020 to 3 Sep 2020.
    • 21 Jun 2018 Planned End Date changed from 22 Jun 2018 to 24 Jan 2020.
    • 21 Jun 2018 Planned primary completion date changed from 22 Jun 2018 to 18 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top